Garadacimab Biosimilar – Anti-F12 mAb – Research Grade from ProteoGenix; catalogue PX-TA1560; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Garadacimab Biosimilar is a novel antibody drug that has recently gained attention in the field of immunotherapy. This biosimilar is a monoclonal antibody (mAb) that specifically targets factor XII (F12), a key protein involved in the coagulation cascade. In this article, we will discuss the structure, activity, and potential applications of Garadacimab Biosimilar as a therapeutic agent.
Garadacimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody. It is composed of two heavy chains and two light chains, each with a molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen binding sites located at the tips of the Y. The heavy and light chains are connected by disulfide bonds, providing stability to the structure.
Garadacimab Biosimilar specifically targets factor XII, a protein involved in the intrinsic pathway of the coagulation cascade. Upon binding to factor XII, Garadacimab Biosimilar inhibits its activity, thereby preventing the formation of blood clots. This mechanism of action makes Garadacimab Biosimilar a promising therapeutic agent for conditions associated with excessive blood clotting, such as deep vein thrombosis, pulmonary embolism, and stroke.
Garadacimab Biosimilar has potential applications in the treatment of various diseases and conditions. Its primary use is in the prevention and treatment of thrombotic events, as mentioned above. However, it may also have therapeutic benefits in other conditions, such as inflammatory diseases and cancer.
As mentioned earlier, Garadacimab Biosimilar inhibits factor XII, which plays a crucial role in the formation of blood clots. Therefore, it can be used as an anti-thrombotic agent to prevent or treat conditions associated with excessive blood clotting. Clinical trials have shown promising results in the prevention of deep vein thrombosis and pulmonary embolism in high-risk patients.
Garadacimab Biosimilar has also shown potential in the treatment of inflammatory diseases, such as rheumatoid arthritis and psoriasis. Factor XII has been implicated in the activation of the immune system and the release of inflammatory mediators. By inhibiting factor XII, Garadacimab Biosimilar may help reduce inflammation and alleviate symptoms in these conditions.
Recent studies have also suggested a potential role for Garadacimab Biosimilar in cancer therapy. Factor XII has been found to promote tumor growth and metastasis by stimulating the formation of blood vessels. By inhibiting factor XII, Garadacimab Biosimilar may inhibit tumor growth and spread. Further research is needed to explore the therapeutic potential of Garadacimab Biosimilar in cancer treatment.
In summary, Garadacimab Biosimilar is a promising antibody drug that specifically targets factor XII and inhibits its activity. Its unique mechanism of action makes it a potential therapeutic agent for a range of conditions, including thrombotic events, inflammatory diseases, and cancer. Further research and clinical trials are needed to fully understand the potential of Garadacimab Biosimilar and its role in improving patient outcomes.
ProteoGenix catalogue number PX-TA1560. For research use only.
Target: Garadacimab Biosimilar – Anti-F12 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Garadacimab Biosimilar – Anti-F12 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
